TFF Pharmaceuticals
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | 1.2m | <1m | 11.7m |
| % growth | - | - | - | - | - | (31 %) | 1366 % |
| EBITDA | (18.7m) | (31.7m) | (31.4m) | (21.8m) | - | - | - |
| Profit | (18.6m) | (31.0m) | (31.8m) | (21.2m) | (19.6m) | (25.9m) | (19.6m) |
| % profit margin | - | - | - | - | (1698 %) | (3238 %) | (167 %) |
| EV / revenue | - | - | - | - | 6.0x | 8.7x | 0.6x |
| EV / EBITDA | -17.0x | -7.1x | -1.2x | -0.8x | - | - | - |
| R&D budget | 10.7m | 21.3m | 18.5m | 12.1m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
$14.0m | Series A | ||
| N/A | $8.2m | Series A | |
| N/A | N/A | IPO | |
| N/A | $25.9m | Post IPO Equity | |
* | N/A | $12.3m | Post IPO Equity |
* | N/A | Grant | |
* | N/A | $1.2m | Post IPO Equity |
* | N/A | $4.8m | Post IPO Equity |
| Total Funding | $22.2m | ||
Related Content
Recent News about TFF Pharmaceuticals
EditTFF Pharmaceuticals specializes in developing advanced inhalation therapies using its proprietary Thin Film Freezing (TFF) technology. The company focuses on creating dry powder formulations for direct-to-lung delivery, which can improve the efficacy and safety of various medications. TFF Pharmaceuticals serves the pharmaceutical and biotechnology sectors, targeting conditions such as lung transplant rejection and fungal infections. The business model involves research and development, clinical trials, and partnerships with other pharmaceutical companies to bring its products to market. Revenue is generated through licensing agreements, milestone payments, and eventual product sales.
Keywords: Thin Film Freezing, inhalation therapies, dry powder, lung delivery, pharmaceutical, biotechnology, drug formulation, clinical trials, lung transplant, fungal infections.